Dateline Resources Fully Funded for Colosseum Gold Project Bankable Feasibility Study
SAN BERNARDINO, CA / ACCESS Newswire / May 19, 2025 / Dateline Resources Limited (OTC:DTREF)(ASX:DTR) is pleased to update its shareholders on the strong financial position and ongoing progress of its flagship Colosseum Gold and Rare Earth Element (REE) Project in California. With a robust cash balance and recent capital inflows, the Company is fully funded to complete the Bankable Feasibility Study (BFS) for the Colosseum Gold Project, a significant milestone in unlocking the project's value.
Key Highlights
Dateline Resources is well-positioned with current cash reserves of $1.95 million, which are expected to increase to $2.3 million upon receipt of part of the proceeds from the Udu Copper Project sale. The Company has raised approximately $1.1 million through recent warrant exercises, reflecting strong shareholder support. The BFS for the 1.1 million ounce Colosseum Gold Project is progressing on schedule, with metallurgical test work now underway. Additionally, planning for a dedicated REE drilling program at Colosseum is being advanced and guided by leading REE experts. The Company is also on track to uplist to the OTCQB Venture Market in Q3 2025, enhancing visibility for U.S. investors.
Financial Strength to Drive Colosseum Forward
Dateline's cash reserves stand at $1.95 million, bolstered by $1.1 million raised from recent warrant exercises. An additional $350,000 is expected from the partial payment of the sale of the non-core Udu Copper Project in Fiji, bringing the total cash balance to approximately $2.3 million. These funds fully cover the costs of the Colosseum Gold Project's BFS, ensuring the Company can advance this critical study without delay. The Company has also seen growing interest from warrant holders seeking to convert their holdings, signaling potential for additional organic funding. By monetizing non-core assets like the Udu Copper Project, Dateline is strategically focusing resources on its high-potential U.S. projects, particularly Colosseum.
'We are in a strong financial position to complete the Colosseum BFS, a pivotal step toward realizing the project's full potential,' said Stephen Baghdadi, Managing Director. 'With the support of our shareholders and disciplined capital management, we are well-equipped to deliver value for our investors.'
Colosseum Gold Project: BFS Progress
The BFS for the Colosseum Gold Project, which hosts a JORC-2012 compliant Mineral Resource of 1.1 million ounces of gold (27.1Mt @ 1.26g/t Au), commenced last month and remains on schedule. Key activities include metallurgical test work, with drill core shipped to Kappes, Cassiday & Associates in Nevada for analysis. Australian Mine Design & Development (AMDAD) is overseeing mine engineering, ensuring a comprehensive study that will guide the project's development. The BFS is expected to be completed in December 2025
Rare Earth Elements: Expanding Colosseum's Potential
In addition to its gold resources, Colosseum holds significant REE potential. Planning for a targeted REE drilling program is advancing, with program design led by renowned experts Dr. Anthony Mariano and Tony Mariano. The Company is finalizing drill targets and logistics and will soon commence the tender process for a drilling contractor. This program, announced on May 5, 2025, underscores Dateline's commitment to maximizing the value of Colosseum's diverse mineral assets.
OTCQB Uplisting to Broaden U.S. Investor Access
Dateline is on track to uplist to the OTCQB Venture Market in Q3 2025, a move designed to increase visibility and accessibility for U.S. investors. This uplisting will complement the Company's ASX listing and support its growth strategy in the U.S. market, where Colosseum is strategically located in the Walker Lane Trend, less than 10km from the Mountain Rare Earth mine.
About Dateline Resources Limited
Dateline Resources Limited (OTC: DTREF, ASX: DTR) is an Australian publicly listed company focused on mining and exploration in North America. The Company owns 100% of the Colosseum Gold-REE Project in San Bernardino County, California, which hosts a 1.1 million ounce gold resource and significant REE potential.
For more information, visit www.datelineresources.com.au or follow us on X at https://twitter.com/Dateline_DTR.
Forward-Looking Statements
This press release contains 'forward-looking statements' within the meaning of applicable securities laws. These statements relate to future events or future performance and include, but are not limited to, statements regarding the potential of the Colosseum Project, the expected benefits of the OTCQB listing, the company's plans for future development, and the strategic importance of the project for U.S. critical minerals supply. Forward-looking statements are based on the company's current expectations, estimates, and projections, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to: fluctuations in the prices of gold and rare earth elements; changes in regulatory requirements or permitting processes; geological or technical challenges in exploration and development; market conditions affecting the company's ability to raise capital; environmental or social factors impacting operations; risks associated with the OTCQB listing process or trading on a new market; environmental and permitting risks associated with operating in a national preserve; uncertainty regarding the delineation of a mineable rare earth elements resource; risks related to the company's ability to secure necessary funding for project development; and potential changes in government policies or priorities affecting the critical minerals sector. The company cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company does not undertake any obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Competent Person Statement
The exploration information in this press release has been reviewed by Mr. Greg Hall, a Chartered Professional of the Australasian Institute of Mining and Metallurgy. Mr. Hall has sufficient experience relevant to the style of mineralization and deposit type to qualify as a Competent Person under the JORC Code. He consents to the inclusion of this information in the context in which it appears.
Contact Information:
Stephen Baghdadi
Managing Director
+61 2 9375 2353
[email protected]
Andrew Rowell
White Noise Communications
+61 400 466 226
[email protected]
SOURCE: Dateline Resources Limited
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
31 minutes ago
- Hamilton Spectator
Stearman Enters Into Definitive Agreement to Acquire NeoCore Uranium Ltd.
VANCOUVER, British Columbia, June 17, 2025 (GLOBE NEWSWIRE) — Stearman Resources Inc. (CSE:STMN) ('Stearman' or the 'Company') announces that it has entered into a definitive share exchange agreement ('NeoCore Agreement') to acquire 100% of the issued and outstanding common shares of NeoCore Uranium Ltd. ('NeoCore'), a private BC company that owns a 100% interest in the NeoCore Uranium Property ('Property'). The Property consists of six mineral claims covering 13,012 hectares, located in the Athabasca Basin in northern Saskatchewan. The Property is located on the eastern flank of the Athabasca Basin, about 65 kilometres southeast of the McArthur River Uranium Mine. It is underlain by Neoarchean River Granites, a geologic unit associated with uranium fertility in both Canadian and global analogs. The Property area is directly adjacent to renowned uranium mining and exploration companies including CanAlaska Uranium Ltd., Skyharbour Resources Ltd. and Baselode Energy Corp. The NeoCore Agreement provides for Stearman to issue 7,500,000 common shares in the capital of the Company (each, a 'Company Share'), at a deemed price of $0.05 per share, in exchange for all the issued and outstanding common shares (the 'NeoCore Shares') of NeoCore (the 'Transaction'). The Company expects to close the Transaction on or before June 30, 2025. The Transaction is subject to certain terms and conditions, including the completion of customary due diligence, the receipt of all required regulatory approval and completion of the Financing (as defined below). There can be no guarantee that the Transaction will be completed as contemplated or at all. The Transaction is at arm's length and there are no finder's fees payable in connection therewith. The Company also announces a non-brokered private placement financing of 2,000,000 units (each, a 'Unit') at a price of $0.05 per Unit for gross proceeds of $100,000 (the 'Financing'). Each Unit will consist of one Company Share and one transferrable common share purchase warrant entitling the holder to purchase one additional Company Share for $0.07 for a period of two years. The net proceeds from the Financing will be used for general corporate purposes. All securities issued pursuant to the Transaction and the Financing will be subject to a hold period of four months and one day as required under applicable securities legislation. After closing the Transaction, the Company plans to file a Business Acquisition Report ('BAR') in accordance with securities regulations within the prescribed time with respect to the acquisition, and it will issue a further news release on filing the BAR. The Company is a mineral exploration company focused on the acquisition, exploration and development of mineral properties in Canada and the USA. The Company currently has an option on the Miniac Property in Quebec, which consists of 78 claims over 4,110 hectares located 35 kilometres north of Amos, Quebec, prospective for gold, zinc, copper and silver, and an option on the Brassie Creek Property, consisting of 9 mineral claims covering 1,862 hectares, located 48 kilometres west of Kamloops, BC, prospective for copper, gold and silver. On Behalf of the Company Howard Milne, Chief Executive Officer For further information, please contact Howard Milne, CEO at 604-377-8994 email hdmcap@ Forward Looking Statements: This press release may contain 'forward‐looking information or statements' within the meaning of Canadian securities laws, which may include, but are not limited to statements relating to its future business plans. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words 'expects', 'plans', 'anticipates', 'believes', 'intends', 'estimates', 'projects', 'potential' and similar expressions, or that events or conditions 'will', 'would', 'may', 'could' or 'should' occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ from those in the forward-looking statements. Such forward-looking information reflects the Company's views with respect to future events and is subject to risks, uncertainties and assumptions. The Company does not undertake to update forward‐looking statements or forward‐looking information, except as required by law. The CSE has neither approved nor disapproved the contents of this press release. Neither the CSE nor its regulation services provider accepts responsibility for the adequacy or accuracy of this release.
Business Insider
2 hours ago
- Business Insider
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (the 'Company'), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Global Market under the symbol 'RAPT' with the new CUSIP number 75382E 208. The Company's common stock will begin trading on a reverse stock split-adjusted basis on June 17, 2025. At the effective time of the reverse split, every eight issued and outstanding shares of the Company's common stock will automatically be combined into one issued and outstanding share of the Company's common stock without any change in the par value per share. Fractional shares will not be issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive a fractional share will be entitled to receive a cash payment. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's relative interest in the Company's equity securities, except for any adjustments for fractional shares. The reverse stock split will not affect the absolute number of the Company's authorized shares of common stock, which will remain at 500,000,000, but the total number of authorized shares of the Company's common stock available for future issuance will increase. In addition, proportionate adjustments will be made to the number of shares underlying, and the exercise or conversion prices of, the Company's outstanding pre-funded warrants and stock options, and to the number of shares of common stock issuable under the Company's equity incentive plans. The reverse stock split will reduce the number of issued and outstanding shares of the Company's common stock from approximately 132.3 million to approximately 16.5 million. RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases. Utilizing our deep and proprietary expertise in immunology, we develop novel therapies that are designed to modulate the critical immune responses underlying these diseases. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'will' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the reverse stock split and the timing thereof, the impact of the reverse stock split on stockholders, including any adjustments that may result from the treatment of fractional shares, pre-funded warrant holders and option holders, the potential impact of the reverse stock split on the bid price of the Company's common stock, the expected number of shares of common stock to be issued and outstanding following the reverse stock split, and other statements that are not historical fact. Detailed information regarding risk factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in RAPT's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2025 and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements, except as required by law.
Business Wire
3 hours ago
- Business Wire
Faraday Future Announces Additional Senior Leadership Entering Into 10b5-1 Stock Purchase Plans
LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) ('Faraday Future', 'FF' or the 'Company'), a California-based global shared intelligent electric mobility ecosystem company, today announced that a number of its senior leadership have entered into 10b5-1 executive stock purchase plans. Under SEC compliance rules, there will be either a 45 or 90-day cooling-off period, after which their broker will automatically execute the stock purchases at times and in amounts in accordance with the plans. A combined total of $60,000 worth of share purchase commitments for FF common stock (including commission fee) were made by various members of FF's leadership team, including Koti Meka, FF CFO, Xiao (Max) Ma, FX brand CEO and Dr. Lei Gu, President of FX Global EV R&D Center. The 10b5-1 plans were officially initiated on June 13, 2025. 'These planned stock purchases reflect the continued confidence by members of FF's core leadership team and serve as a positive indicator by all of them in FF's long-term vision and commitment to our mission and products,' said YT Jia, FF Founder and Global Co-CEO. 'This is yet another demonstration of our core principle: Stockholders First.' ABOUT FARADAY FUTURE Faraday Future is a California-based global shared intelligent electric mobility ecosystem company. Founded in 2014, the Company's mission is to disrupt the automotive industry by creating a user-centric, technology-first, and smart driving experience. Faraday Future's flagship model, the FF91, exemplifies its vision for luxury, innovation, and performance. The FX strategy aims to introduce mass production models equipped with state-of-the-art luxury technology similar to the FF 91, targeting a broader market with middle-to-low price range offerings. FF is committed to redefining mobility through AI innovation. Join us in shaping the future of intelligent transportation. For more information, please visit FORWARD LOOKING STATEMENTS This press release includes 'forward looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words 'plan to,' 'can,' 'will,' 'should,' 'future,' 'potential,' and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding 10b5-1 purchase plans, are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, among others: each executive's ability to cancel or amend his 10b5-1 purchase plan; potential volume limitations under Rule 144 or Rule 145 of the Securities Act of 1933, as amended, or Regulation M; the possible suspension of purchases due to a trading suspension, legal, regulatory or contractual restrictions; or a subsequent determination that a 10b5-1 plan does not comply with Rule 10b5-1 or other applicable securities laws. You should carefully consider the foregoing factors and the other risks and uncertainties described in the 'Risk Factors' section of the Company's Form 10-K filed with the SEC on March 31, 2025, and other documents filed by the Company from time to time with the SEC.
